Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Onset's SoloPath transseptal catheter:

This article was originally published in Clinica

Executive Summary

Onset Medical has CE marked its SoloPath percutaneous transseptal access catheter for sale in Europe, and plans to market it in the EU and "select countries worldwide". The catheter uses the Irvine, California-based firm's controlled deployment technology (CDT) to allow surgeons to access the left atrium and pulmonary veins. The diameter of the catheter when it enters the body is around 50% of the size of conventional access devices, Onset claims, but once positioned, it can be expanded to maintain access to the treatment site, creating an internal diameter larger than conventional devices. SoloPath received US FDA 510(k) clearance in March 2007 (see Clinica No 1249, p 22).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT046774

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel